Clinical Trial Update: Mycophenolate Mofetil for Reducing Cardiovascular Risk in Renal Transplant Recipients [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating mycophenolate mofetil to reduce cardiovascular risk in kidney transplant recipients has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiovascular Diseases
• Kidney Transplantation

Drugs mentioned

• MYCOPHENOLATE MOFETIL (MYCOPHENOLATE MOFETIL)

Snippet

Sponsor: Ramesh Prasad | Conditions: Kidney Transplantation, Cardiovascular Diseases | Phase 3 | Status: TERMINATED